GALT EBITDA | GALECTIN THERAPEUTICS INC.

GALECTIN THERAPEUTICS INC. (GALT) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$3.98M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$4.08M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$4.20M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$4.63M; Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history: 2012-12-31 to 2018-12-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$3.98M	(m)	(m)	(m)	(m)	-$2.44M*	(m)	$2.13M	(m)	(m)
2026-03-31	Reported	(m)	-$4.08M	(m)	(m)	(m)	(m)	-$3.87M	(m)	$2.23M	(m)	(m)
2025-09-30	Reported	(m)	-$4.20M	(m)	(m)	(m)	(m)	-$3.54M*	(m)	$2.61M	(m)	(m)
2025-06-30	Reported	(m)	-$4.63M	(m)	(m)	(m)	(m)	-$6.60M*	(m)	$3.26M	(m)	(m)
2025-03-31	Reported	(m)	-$7.90M	(m)	(m)	(m)	(m)	-$7.69M	(m)	$6.49M	(m)	(m)
2024-09-30	Reported	(m)	-$9.07M	(m)	(m)	(m)	(m)	-$8.54M*	(m)	$7.59M	(m)	(m)
2024-06-30	Reported	(m)	-$11.29M	(m)	(m)	(m)	(m)	-$8.33M*	(m)	$9.81M	(m)	(m)
2024-03-31	Reported	(m)	-$9.65M	(m)	(m)	(m)	(m)	-$12.11M	(m)	$8.05M	(m)	(m)
2023-09-30	Reported	(m)	-$9.17M	(m)	(m)	(m)	(m)	-$7.64M*	(m)	$7.73M	(m)	(m)
2023-06-30	Reported	(m)	-$9.00M	(m)	(m)	(m)	(m)	-$9.83M*	(m)	$7.37M	(m)	(m)
2023-03-31	Reported	(m)	-$10.34M	(m)	(m)	(m)	(m)	-$10.79M	(m)	$8.80M	(m)	(m)
2022-09-30	Reported	(m)	-$8.12M	(m)	(m)	(m)	(m)	-$8.35M*	(m)	$6.60M	(m)	(m)
2022-06-30	Reported	(m)	-$9.66M	(m)	(m)	(m)	(m)	-$7.43M*	(m)	$8.07M	(m)	(m)
2022-03-31	Reported	(m)	-$9.94M	(m)	(m)	(m)	(m)	-$8.04M	(m)	$8.06M	(m)	(m)
2021-09-30	Reported	(m)	-$8.24M	(m)	(m)	(m)	(m)	-$5.00M*	(m)	$6.61M	(m)	(m)
2021-06-30	Reported	(m)	-$8.19M	(m)	(m)	(m)	(m)	-$5.98M*	(m)	$6.45M	(m)	(m)
2021-03-31	Reported	(m)	-$6.32M	(m)	(m)	(m)	(m)	-$6.38M	(m)	$4.90M	(m)	(m)
2020-09-30	Reported	(m)	-$5.93M	(m)	(m)	(m)	(m)	-$8.21M*	(m)	$4.78M	(m)	(m)
2020-06-30	Reported	(m)	-$6.10M	(m)	(m)	(m)	(m)	-$2.60M*	(m)	$4.68M	(m)	(m)
2020-03-31	Reported	(m)	-$3.58M	(m)	(m)	(m)	(m)	-$4.37M	(m)	$2.14M	(m)	(m)
2019-09-30	Reported	(m)	-$2.86M	(m)	(m)	(m)	(m)	-$1.48M*	(m)	$1.50M	(m)	(m)
2019-06-30	Reported	(m)	-$3.02M	(m)	(m)	(m)	(m)	-$2.33M*	(m)	$1.52M	(m)	(m)
2019-03-31	Reported	(m)	-$2.37M	(m)	(m)	(m)	(m)	-$3.28M	(m)	$646.00K	(m)	(m)
2018-09-30	Reported	(m)	-$2.68M	(m)	(m)	(m)	(m)	-$1.58M*	(m)	$1.50M	(m)	(m)
2018-06-30	Reported	(m)	-$3.76M	(m)	(m)	(m)	(m)	-$3.08M*	(m)	$1.48M	(m)	(m)
2018-03-31	Reported	(m)	-$4.18M	(m)	(m)	(m)	(m)	-$3.52M	(m)	$2.30M	(m)	(m)
2017-12-31	Reported	-$2.37M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	-$4.41M*	-$4.41M	$0.00*	(m)	(m)	(m)	-$3.12M*	(m)	$3.50M	(m)	(m)
2017-06-30	Reported	-$4.51M*	-$4.51M	$0.00*	(m)	(m)	(m)	(m)	(m)	$3.44M	(m)	(m)
2017-03-31	Reported	-$4.95M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$3.77M	(m)	(m)
2016-12-31	Reported	-$4.6M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Reported	-$4.54M*	-$4.54M	$2.00K*	(m)	(m)	(m)	(m)	(m)	$3.29M	(m)	(m)
2016-06-30	Reported	-$5.53M*	-$5.53M	$2.00K*	(m)	(m)	(m)	(m)	(m)	$4.23M	(m)	(m)
2016-03-31	Reported	-$6.81M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$4.38M	(m)	(m)
2015-12-31	Reported	-$4.68M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Reported	-$5.90M*	-$5.90M	$2.00K*	(m)	(m)	(m)	(m)	(m)	$4.46M	(m)	(m)
2015-06-30	Reported	-$4.66M*	-$4.66M	$2.00K*	(m)	(m)	(m)	(m)	(m)	$2.60M	(m)	(m)
2015-03-31	Reported	-$4.84M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$3.14M	(m)	(m)
2014-12-31	Reported	-$3.73M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-09-30	Reported	-$3.47M*	-$3.48M	$3.00K*	(m)	(m)	(m)	(m)	(m)	$1.98M	(m)	(m)
2014-06-30	Reported	-$3.37M*	-$3.38M	$3.00K*	(m)	(m)	(m)	(m)	(m)	$1.59M	(m)	(m)
2014-03-31	Reported	-$4.84M	(m)	(m)	(m)	(m)	(m)	-$3.62M	(m)	$2.77M	(m)	(m)
2013-12-31	Reported	-$2.8M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-09-30	Reported	-$3.54M*	-$3.54M	$3.00K*	(m)	(m)	(m)	-$1.48M*	(m)	$1.19M	(m)	(m)
2013-06-30	Reported	(m)	-$2.55M	(m)	(m)	(m)	(m)	(m)	(m)	$1.35M	(m)	(m)
2013-06-30	Reported	-$2.54M*	-$2.55M	$3.00K*	(m)	(m)	(m)	-$1.93M*	(m)	$1.35M	(m)	(m)
2013-03-31	Reported	-$3.21M	(m)	(m)	(m)	(m)	(m)	-$2.42M	(m)	$1.75M	(m)	(m)
2012-09-30	Reported	(m)	-$2.90M	(m)	(m)	(m)	(m)	-$2.08M*	(m)	$1.41M	(m)	(m)
2012-06-30	Reported	(m)	-$2.67M	(m)	(m)	(m)	(m)	(m)	(m)	$1.22M	(m)	(m)
2012-03-31	Reported	(m)	-$1.95M	(m)	(m)	(m)	(m)	-$1.49M	(m)	$901.00K	(m)	(m)
2011-09-30	Reported	(m)	-$2.03M	(m)	(m)	(m)	(m)	-$1.25M*	(m)	$655.00K	(m)	(m)
2011-06-30	Reported	(m)	-$2.99M	(m)	(m)	(m)	(m)	-$1.52M*	(m)	$1.29M	(m)	(m)
2011-03-31	Reported	(m)	-$2.01M	(m)	(m)	(m)	(m)	-$1.37M	(m)	$744.00K	(m)	(m)
2010-09-30	Reported	(m)	-$1.21M	(m)	(m)	(m)	(m)	-$827.00K*	(m)	$313.00K	(m)	(m)
2010-06-30	Reported	(m)	-$1.35M	(m)	(m)	(m)	(m)	(m)	(m)	$234.00K	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$20.09M	(m)	(m)	(m)	(m)	-$23.88M	(m)	$14.29M	(m)	$0.00
2024-12-31	Reported	(m)	-$42.43M	(m)	(m)	(m)	(m)	-$41.77M	(m)	$36.57M	(m)	$0.00
2023-12-31	Reported	(m)	-$38.07M	(m)	(m)	(m)	(m)	-$32.97M	(m)	$32.13M	(m)	(m)
2022-12-31	Reported	(m)	-$38.35M	(m)	(m)	(m)	(m)	-$31.06M	(m)	$31.74M	(m)	(m)
2021-12-31	Reported	(m)	-$30.18M	(m)	(m)	(m)	(m)	-$24.31M	(m)	$23.82M	(m)	(m)
2020-12-31	Reported	(m)	-$23.44M	(m)	(m)	(m)	(m)	-$20.60M	(m)	$17.98M	(m)	(m)
2019-12-31	Reported	(m)	-$13.44M	(m)	(m)	(m)	(m)	-$10.85M	(m)	$7.47M	(m)	(m)
2018-12-31	Reported	-$13.6M	(m)	(m)	(m)	(m)	(m)	-$10.18M	(m)	$6.47M	(m)	(m)
2017-12-31	Reported	-$16.25M	(m)	(m)	(m)	(m)	(m)	-$15.89M	(m)	$11.72M	(m)	(m)
2016-12-31	Reported	-$21.47M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$15.32M	(m)	(m)
2015-12-31	Reported	-$20.07M	(m)	(m)	(m)	(m)	$0.00	(m)	(m)	$13.11M	(m)	(m)
2014-12-31	Reported	-$15.42M	(m)	(m)	(m)	(m)	$0.00	(m)	(m)	$8.43M	(m)	(m)
2013-12-31	Reported	-$12.09M	(m)	(m)	(m)	(m)	$0.00	-$7.48M	(m)	$5.69M	(m)	(m)
2012-12-31	Reported	-$9.89M	(m)	(m)	(m)	(m)	$5.00K	-$7.50M	(m)	$4.53M	(m)	(m)
2011-12-31	Reported	(m)	-$10.41M	(m)	(m)	(m)	$5.00K	-$5.68M	(m)	$3.55M	(m)	(m)
2010-12-31	Reported	(m)	-$4.88M	(m)	(m)	(m)	(m)	-$3.10M	(m)	$1.07M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Arcturus Therapeutics Holdings Inc. (ARCT)		$0.402B	-2.05
Turn Therapeutics Inc. (TTRX)	United States	$0.397B	-25.68
Opus Genetics, Inc. (IRD)	United States	$0.406B	-3.16
RELMADA THERAPEUTICS, INC. (RLMD)	United States	$0.406B	-11.92
ARS Pharmaceuticals, Inc. (SPRY)	United States	$0.414B	-3.70
Atea Pharmaceuticals, Inc. (AVIR)	United States	$0.414B	-2.26
Rezolute, Inc. (RZLT)	United States	$0.382B	-6.45
DiaMedica Therapeutics Inc. (DMAC)	United States	$0.423B	-10.11
PROTHENA CORP PUBLIC LTD CO (PRTA)	Ireland	$0.428B	-11.53
CYPHERPUNK TECHNOLOGIES INC. (CYPH)	United States	$0.438B	-75.63